OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.

Trial Details

NCT ID
NCT05333328
Phase
PHASE4
Sponsor
Gangnam Severance Hospital
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Ovarian function suppression with endocrine treatments
Locations (sample)
  • Seoul, Korea, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • ER+HER2- breast cancer
  • Premenopausal and age \<=50
  • N1 including micrometastasis
  • Genomic Low Risk by OncoFREE test® (1-20)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →